Tap Pharmaceutical
As of the edition of 20 October 2026, Tap Pharmaceutical runs 2 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lansoprazole | none listed | 0 |
| Cefmenoxime | none listed | 0 |
A route B row is one company at one target.